Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis

NCT05692154 is registered in ClinicalTrials.gov with Opella Healthcare Group SAS, a Sanofi Company as lead sponsor.

NCT NCT05692154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05692154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis
Lead sponsor
Opella Healthcare Group SAS, a Sanofi Company
Phase
Phase 3
Overall status
Completed
Start date
January 23, 2023
Completion date
March 14, 2023
Enrollment
95 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal allergic rhinitis